Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
Background: Anti-tumor necrosis factor biological agents had been proved to have a dramatic effect in ankylosing spondylitis (AS). We aimed to determine the efficacy and safety of crossover effects of adalimumab vs. etanercept in AS patients.Methods: A randomized, open-label crossover study was done...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020-10-01
|
| Serija: | Frontiers in Medicine |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fmed.2020.566160/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|